AstraZeneca earnings beat expectations as steady drug sales boost revenues

Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales.
The total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share.
The shares of the company saw an increase of 5.32% reacting positively to the quarterly results.

AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24.

Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and continued growth in Alliance Revenue from partnered medicines.

Core EPS increased 13% to $2.06. The increase in Core EPS was lower than total revenue growth mainly because of a $241m gain in the previous year's period on the disposal of Pulmicort Flexhaler US rights.

The total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share as announced by the company at the Annual General Meeting on 11 April 2024.

The shares of the company saw an increase of 5.32% reacting positively to the quarterly results.